Cargando…

Utility of VS38c in the diagnostic and prognostic assessment of osteosarcoma and other bone tumours/tumour-like lesions

BACKGROUND: VS38c is a monoclonal antibody that recognises a rough endoplasmic reticulum (rER) intracellular antigen termed cytoskeleton-linking membrane protein 63. rER is typically found in viable tumour cells and is abundant in osteosarcoma cells. The aim of this study was to determine the diagno...

Descripción completa

Detalles Bibliográficos
Autores principales: Hookway, E. S., Orosz, Z., Uchihara, Y., Grigoriadis, A., Hassan, A. B., Oppermann, U., Athanasou, N. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603185/
https://www.ncbi.nlm.nih.gov/pubmed/28936339
http://dx.doi.org/10.1186/s13569-017-0083-5
_version_ 1783264690809339904
author Hookway, E. S.
Orosz, Z.
Uchihara, Y.
Grigoriadis, A.
Hassan, A. B.
Oppermann, U.
Athanasou, N. A.
author_facet Hookway, E. S.
Orosz, Z.
Uchihara, Y.
Grigoriadis, A.
Hassan, A. B.
Oppermann, U.
Athanasou, N. A.
author_sort Hookway, E. S.
collection PubMed
description BACKGROUND: VS38c is a monoclonal antibody that recognises a rough endoplasmic reticulum (rER) intracellular antigen termed cytoskeleton-linking membrane protein 63. rER is typically found in viable tumour cells and is abundant in osteosarcoma cells. The aim of this study was to determine the diagnostic and prognostic utility of VS38c in the histological assessment of osteosarcoma and other bone tumours/tumour-like leisons. METHODS: Immunohistochemical staining with VS38c was carried out on formalin-fixed specimens of osteosarcoma (pre/post-chemotherapy) and a wide range of benign and malignant bone lesions. In addition, VS38c staining of cultures of MG63 and Sa0S2 osteosarcoma cell cultures. (±cisplatin and actinomycin D-treatment) was analysed. RESULTS: VS38c strongly stained tumour cells in all low-grade and high-grade osteosarcomas and in undifferentiated sarcomas and high-grade chondrosarcomas. There was little or no VS38c staining of low-grade chondrosarcomas or chordomas and variable staining of Ewing sarcomas. Osteoblasts in benign bone-forming tumours and mononuclear stromal cells in chondroblastomas, giant cell tumours and non-ossifying fibromas strongly stained for VS38c. VS38c staining was absent in cisplatin and actinomycin D treated Sa0S2 and MG63 cells. In specimens of osteosarcoma post-neoadjuvant therapy, VS38c staining was absent in most morphologically necrotic areas of tumor although some cells with pyknotic nuclei stained for VS38c in these areas. Most tumour cells exhibiting atypical nuclear forms were not stained by VS38c. CONCLUSIONS: Our findings show that VS38c is a sensitive but not specific diagnostic marker of osteosarcoma. Staining with VS38c identifies viable osteosarcoma cells, a feature which may be useful in the assessment of percentage tumour necrosis post-neoadjuvant chemotherapy.
format Online
Article
Text
id pubmed-5603185
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-56031852017-09-21 Utility of VS38c in the diagnostic and prognostic assessment of osteosarcoma and other bone tumours/tumour-like lesions Hookway, E. S. Orosz, Z. Uchihara, Y. Grigoriadis, A. Hassan, A. B. Oppermann, U. Athanasou, N. A. Clin Sarcoma Res Research BACKGROUND: VS38c is a monoclonal antibody that recognises a rough endoplasmic reticulum (rER) intracellular antigen termed cytoskeleton-linking membrane protein 63. rER is typically found in viable tumour cells and is abundant in osteosarcoma cells. The aim of this study was to determine the diagnostic and prognostic utility of VS38c in the histological assessment of osteosarcoma and other bone tumours/tumour-like leisons. METHODS: Immunohistochemical staining with VS38c was carried out on formalin-fixed specimens of osteosarcoma (pre/post-chemotherapy) and a wide range of benign and malignant bone lesions. In addition, VS38c staining of cultures of MG63 and Sa0S2 osteosarcoma cell cultures. (±cisplatin and actinomycin D-treatment) was analysed. RESULTS: VS38c strongly stained tumour cells in all low-grade and high-grade osteosarcomas and in undifferentiated sarcomas and high-grade chondrosarcomas. There was little or no VS38c staining of low-grade chondrosarcomas or chordomas and variable staining of Ewing sarcomas. Osteoblasts in benign bone-forming tumours and mononuclear stromal cells in chondroblastomas, giant cell tumours and non-ossifying fibromas strongly stained for VS38c. VS38c staining was absent in cisplatin and actinomycin D treated Sa0S2 and MG63 cells. In specimens of osteosarcoma post-neoadjuvant therapy, VS38c staining was absent in most morphologically necrotic areas of tumor although some cells with pyknotic nuclei stained for VS38c in these areas. Most tumour cells exhibiting atypical nuclear forms were not stained by VS38c. CONCLUSIONS: Our findings show that VS38c is a sensitive but not specific diagnostic marker of osteosarcoma. Staining with VS38c identifies viable osteosarcoma cells, a feature which may be useful in the assessment of percentage tumour necrosis post-neoadjuvant chemotherapy. BioMed Central 2017-09-18 /pmc/articles/PMC5603185/ /pubmed/28936339 http://dx.doi.org/10.1186/s13569-017-0083-5 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Hookway, E. S.
Orosz, Z.
Uchihara, Y.
Grigoriadis, A.
Hassan, A. B.
Oppermann, U.
Athanasou, N. A.
Utility of VS38c in the diagnostic and prognostic assessment of osteosarcoma and other bone tumours/tumour-like lesions
title Utility of VS38c in the diagnostic and prognostic assessment of osteosarcoma and other bone tumours/tumour-like lesions
title_full Utility of VS38c in the diagnostic and prognostic assessment of osteosarcoma and other bone tumours/tumour-like lesions
title_fullStr Utility of VS38c in the diagnostic and prognostic assessment of osteosarcoma and other bone tumours/tumour-like lesions
title_full_unstemmed Utility of VS38c in the diagnostic and prognostic assessment of osteosarcoma and other bone tumours/tumour-like lesions
title_short Utility of VS38c in the diagnostic and prognostic assessment of osteosarcoma and other bone tumours/tumour-like lesions
title_sort utility of vs38c in the diagnostic and prognostic assessment of osteosarcoma and other bone tumours/tumour-like lesions
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603185/
https://www.ncbi.nlm.nih.gov/pubmed/28936339
http://dx.doi.org/10.1186/s13569-017-0083-5
work_keys_str_mv AT hookwayes utilityofvs38cinthediagnosticandprognosticassessmentofosteosarcomaandotherbonetumourstumourlikelesions
AT oroszz utilityofvs38cinthediagnosticandprognosticassessmentofosteosarcomaandotherbonetumourstumourlikelesions
AT uchiharay utilityofvs38cinthediagnosticandprognosticassessmentofosteosarcomaandotherbonetumourstumourlikelesions
AT grigoriadisa utilityofvs38cinthediagnosticandprognosticassessmentofosteosarcomaandotherbonetumourstumourlikelesions
AT hassanab utilityofvs38cinthediagnosticandprognosticassessmentofosteosarcomaandotherbonetumourstumourlikelesions
AT oppermannu utilityofvs38cinthediagnosticandprognosticassessmentofosteosarcomaandotherbonetumourstumourlikelesions
AT athanasouna utilityofvs38cinthediagnosticandprognosticassessmentofosteosarcomaandotherbonetumourstumourlikelesions